Isomab Reports Positive Clinical Data on Angiogenic Therapy for Heart Disease

Biotech firm Isomab presents preliminary clinical trial results indicating that angiogenic treatment approaches demonstrate strong safety profiles for patients with coronary artery disease.

7 Sept, 07:00 — 7 Sept, 07:00

Post Share

Sources

Showing 1 of 1 sources

morningstar2d ago

Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease - Morningstar

Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease Morningstar

Read full article →

Isomab Reports Positive Clinical Data on Angiogenic Therapy for Heart Disease

Sources

Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease - Morningstar

Related Stories

US Justice Department Probes Nvidia’s Licensing Deal With Groq

Commodity Prices Surge Near 18-Year Highs Amid Scarcity Fears

Oil Prices Surge Past $100 Following Middle East Shipping Attacks

Energy Transfer Moves Primary Stock Listing from New York to the Texas Stock Exchange